Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphoma.
Benjamini O, Fried S, Shouval R, Flynn JR, Beyar-Katz O, Leslie LA, Zucherman T, Yerushalmi R, Shem-Tov N, Palomba ML, Danylesko I, Sdayoor I, Malka H, Itzhaki O, Suh H, Devlin SM, Marcus R, Dahi PB, Jacoby E, Shah GL, Sauter CS, Ip A, Perales MA, Nagler A, Shimoni A, Scordo M, Avigdor A. Benjamini O, et al. Among authors: ip a. Haematologica. 2024 Nov 1;109(11):3566-3577. doi: 10.3324/haematol.2023.284664. Haematologica. 2024. PMID: 38899351 Free PMC article.
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Donato ML, Park S, Baker M, Korngold R, Morawski A, Geng X, Tan M, Ip A, Goldberg S, Rowley S, Chow K, Brown E, Zenreich J, McKiernan P, Buttner K, Ullrich A, Long L, Feinman R, Ricourt A, Kemp M, Vendivil M, Suh H, Balani B, Cicogna C, Sebti R, Al-Khan A, Sperber S, Desai S, Fanning S, Arad D, Go R, Tam E, Rose K, Sadikot S, Siegel D, Gutierrez M, Feldman T, Goy A, Pecora A, Biran N, Leslie L, Gillio A, Timmapuri S, Boonstra M, Singer S, Kaur S, Richards E, Perlin DS. Donato ML, et al. Among authors: ip a. JCI Insight. 2021 Mar 22;6(6):e143196. doi: 10.1172/jci.insight.143196. JCI Insight. 2021. PMID: 33571168 Free PMC article. Clinical Trial.
Anti-spike antibody response to the COVID vaccine in lymphoma patients.
Della Pia A, Kim GYG, Ip A, Ahn J, Liu Y, Kats S, Koropsak M, Lukasik B, Contractor A, Amin K, Ayyagari L, Zhao C, Gupta A, Batistick M, Leslie LA, Goy AH, Feldman TA. Della Pia A, et al. Among authors: ip a. PLoS One. 2022 Dec 1;17(12):e0266584. doi: 10.1371/journal.pone.0266584. eCollection 2022. PLoS One. 2022. PMID: 36454941 Free PMC article.
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Scordo M, Flynn JR, Gonen M, Devlin SM, Parascondola A, Tomas AA, Shouval R, Brower J, Porter DL, Schuster SJ, Bachanova V, Maakaron J, Maziarz RT, Chen AI, Nastoupil LJ, McGuirk JP, Oluwole OO, Ip A, Leslie LA, Bishop MR, Riedell PA, Perales MA. Scordo M, et al. Among authors: ip a. Blood Adv. 2023 Sep 26;7(18):5579-5585. doi: 10.1182/bloodadvances.2023010302. Blood Adv. 2023. PMID: 37522731 Free PMC article.
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A, Petrillo A, Della Pia A, Lee GG, Gill S, Varughese T, Zenreich J, Gutierrez M, Zhang J, Ahn J, Bharani V, Nejad AS, Pascual L, Feldman TA, Leslie LA, Goy AH. Ip A, et al. Leuk Lymphoma. 2023 Dec;64(14):2225-2235. doi: 10.1080/10428194.2023.2259528. Epub 2023 Dec 25. Leuk Lymphoma. 2023. PMID: 37740588 Free article. Clinical Trial.
Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation.
Rowley SD, Gunning TS, Pelliccia M, Della Pia A, Lee A, Behrmann J, Bangolo A, Jandir P, Zhang H, Kaur S, Suh HC, Donato M, Albitar M, Ip A. Rowley SD, et al. Among authors: ip a. Cancers (Basel). 2024 Mar 29;16(7):1357. doi: 10.3390/cancers16071357. Cancers (Basel). 2024. PMID: 38611035 Free PMC article.
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
Rosenthal A, Munoz J, Jun M, Wang T, Mutebi A, Wang A, Yang S, Osei-Bonsu K, Elliott B, Rivas Navarro F, Yu J, Brodkin S, Sacchi M, Ip A. Rosenthal A, et al. Among authors: ip a. J Hematol Oncol. 2024 Aug 16;17(1):69. doi: 10.1186/s13045-024-01594-x. J Hematol Oncol. 2024. PMID: 39152509 Free PMC article.
188 results